Most of them are difficult to treat because they are not found in the early stages, and the 5-year survival rate is 16.8%, a very low rate. Lung cancer is divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), and most lung cancer is NSCLC, accounting for 85% of lung cancer patients. Epidermal growth factor receptor (EGFR) mutations were found in 25% of patients with NSCLC.
Patients with third stage or later stage lung cancer are treated with chemotherapy. Especially, patients with NSCLC prefer EGFR-targeted chemotherapy. However, since most patients have a variety of cancer genes besides EGFR, it is difficult to treat them with only anti-cancer drugs approved for lung cancer treatment.
Lung cancer has more relapses and metastases than other cancers, and 55.8% of patients with NSCLC have distant metastatic disease at initial diagnosis, and 20 to 50% of patients who undergo curative surgery have local recurrences.
Molecule-targeted anti-cancer drugs are well established as anti-lung cancer therapy. However, they have a variety of carcinogenic molecules and through the mutation of target molecules, resistance is often developed and recurrence and metastasis often occurs. This is why diverse treatment drugs for lung cancer, especially NSCLC, needs to be developed.
The anti-cancer drug by BeyondBio is a new molecular targeted anti-cancer drug that can regulate cancer recurrence and resistance. Because it has a relatively higher distribution rate into the lung tissue, it is expected to be an excellent anti-cancer drug that can exhibit good anti-cancer effects even with small doses.